One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis

Background and purpose:  To define the predictive value of clinical and magnetic resonance imaging (MRI) characteristics in identifying relapsing‐remitting multiple sclerosis (RR‐MS) patients with sustained disability progression during interferon beta (IFNB) treatment. Methods:  All patients receiv...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of neurology Jg. 16; H. 11; S. 1202 - 1209
Hauptverfasser: Prosperini, L., Gallo, V., Petsas, N., Borriello, G., Pozzilli, C.
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Oxford, UK Blackwell Publishing Ltd 01.11.2009
Schlagworte:
Adolescent
Adult
Age of Onset
Child
Disease Progression
Female
Follow-Up Studies
Humans
interferon beta
Interferon-beta - therapeutic use
Longitudinal Studies
magnetic resonance imaging
Magnetic Resonance Imaging - methods
Male
Middle Aged
multiple sclerosis
Multiple Sclerosis, Relapsing-Remitting - drug therapy
Predictive Value of Tests
response to therapy
Risk Factors
Severity of Illness Index
Time Factors
Treatment Outcome
ISSN:1351-5101, 1468-1331, 1468-1331
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background and purpose:  To define the predictive value of clinical and magnetic resonance imaging (MRI) characteristics in identifying relapsing‐remitting multiple sclerosis (RR‐MS) patients with sustained disability progression during interferon beta (IFNB) treatment. Methods:  All patients receiving treatment with one of the available IFNB formulations for at least 1 year were included in this single‐centre, prospective and post‐marketing study. Demographic, clinical and MRI data were collected at IFNB start and at 1 year of therapy; patients were followed‐up at least yearly. Poor clinical response was defined as the occurrence of a sustained disability progression of ≥1 point in the Expanded Disability Status Scale (EDSS) during the follow‐up period. Results:  Out of 454 RR‐MS patients starting IFNB therapy, data coming from 394 patients with a mean follow‐up of 4.8 (2.4) years were analysed. Sixty patients were excluded because of too short follow‐up. Less than 1/3 (30.4%) of the patients satisfied the criterion of ‘poor responders’. Patients presenting new lesions on T2‐weighted MRI scan after 1 year of therapy (compared with baseline) had a higher risk of being poor responder to treatment with IFNB during the follow‐up period (HR 16.8, 95% CI 7.6–37.1, P < 0.001). An augmented risk increasing the number of lesions was observed, with a 10‐fold increase for each new lesion. Conclusions:  Developing new T2‐hyperintense lesions during IFNB treatment was the best predictor of long‐term poor response to therapy. MRI scans performed after 1 year of IFNB treatment may be useful in contributing to early identification of poor responders.
Bibliographie:ArticleID:ENE2708
istex:FC4EEB0C94B0B1068982C8C801AFC93BDD5DD32A
ark:/67375/WNG-9NXBL0ML-2
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1351-5101
1468-1331
1468-1331
DOI:10.1111/j.1468-1331.2009.02708.x